Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, has announced further notable progress in the manufacture of its first LIGHT system.
Patient positioning system: The group said multiple components of the treatment room had been manufactured, inspected and tested by its partner P-Cure Ltd, ahead of their integration to form a complete patient treatment system.
It said the patient positioning subsystem, which included the patient treatment chair and robotic arm which moved the chair and patient, was complete and had been designed to leverage LIGHT's next-generation features.
It said that as other subsystems were completed, such as imaging and treatment management software, they would be integrated to form the whole patient positioning system, which remained on track to be fully developed by the end of 2017.
Beam firing through RFQ: The company said that as indicated in the investor presentation and update of 6 March, the proton beam was fired through the radio frequency quadrupole (RFQ), at its maximum expected energy, in February.
It said: "Subsequent work has focused on enhancing the proton source that feeds the RFQ; repeatability of beam firing, intensive usage to facilitate high patient throughput and maximising safety controls are all key elements of LIGHT."
The company also announced that it had received delivery of the LIGHT system's ionisation chamber, from its partner Pyramid Technical Consultants Inc, to its Geneva testing facility.
It said: "The ionisation chamber is a critical element of the LIGHT system's overall safety system, monitoring beam position, spot size and dosage and is situated at the delivery end of the system after the main accelerating modules.
"The novel design of the chamber is matched to the unique properties of LIGHT and performs a precise measurement of the position (in horizontal and vertical axes) of the proton beam, with respect to its desired location, and is a critical element of the LIGHT system's patient treatment system.
"It also accurately monitors the dose (number of protons) delivered to the target.
"The properties of the LIGHT ionisation chamber allow these measurements to be taken, on a pulse by pulse basis, ensuring accuracy and safety throughout treatment, to a level that cannot be matched by older proton therapy technologies."
Chief executive Nicolas Serandour said: "As I outlined in my update to shareholders in March, the company remains focused on delivering the technical development of our first LIGHT machine and its ultimate installation at Harley Street, and I am very pleased with the progress we are making.
"We will continue to update the market with newsflow on the integration of the LIGHT system's components, with developments on the CCL units, addition of the SCDTLs to the RFQ and on the patient positioning system anticipated in the coming weeks and months."
At 9:28am: (LON:AVO) Advanced Oncotherapy PLC share price was 0p at 15.75p